T. Kang

Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience

D. Peereboom, T. Jin, T. Kang, 2007 .

Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab

S. Smith, A. Advani, L. Rybicki, 2011, Bone Marrow Transplantation.

Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)

C. Hudis, M. Theodoulou, M. Robson, 2008 .

Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response

W. Ye, S. Groshen, P. Nichols, 2007, BJU international.

Muscular amyloidoma presenting as inguinal masses in multiple myeloma

C. Joung, T. Kang, W.-S. Lee, 2005, Scandinavian journal of rheumatology.

Thalidomide use and digital gangrene.

C. J. Lowe, M. Sekeres, T. Kang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma

A. Advani, L. Rybicki, M. Sekeres, 2007, Bone Marrow Transplantation.

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

D. Peereboom, T. Kang, H. Elinzano, 2008, Journal of Neuro-Oncology.